KF
ALXN

Krilogy Financial’s Alexion Pharmaceuticals ALXN Stock Holding History

Krilogy Financial’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-21
Closed -$2K – 691
2018
Q1 		$2K Hold
21
– – ﹤0.01% 712
2017
Q4 		$3K Hold
21
– – ﹤0.01% 665
2017
Q3 		$3K Buy
+21
New +$2.85K ﹤0.01% 715

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Krilogy Financial's ALXN Position: Q2 2018 in Review

Krilogy Financial sold out of Alexion Pharmaceuticals (ALXN) in Q2 2018, closing a stake of 21 shares — an estimated $2K sold.

Krilogy Financial first reported a position in ALXN in Q3 2017 and held it in 3 quarters. The position peaked at $3K in Q4 2017. 600 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

  • Krilogy Financial reported no remaining Alexion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Krilogy Financial sold 21 Alexion Pharmaceuticals shares in Q2 2018, an estimated $2K.
  • Krilogy Financial first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 3 quarters.
  • Krilogy Financial's Alexion Pharmaceuticals position peaked at $3K in Q4 2017.
  • 600 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on Krilogy Financial's 13F filing for Q2 2018, filed 15 Aug 2018.